Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

ChinaBio® Publishes Proprietary China CRO/CMO List on goBalto

publication date: Apr 30, 2009
 | 
author/source: Richard Daverman, PhD

ChinaBio® LLC is making its proprietary list of over 260 China-based Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) available on goBalto.com. goBalto is a recently launched online web-based partnering site for the pharmaceutical industry that allows members to find partners, share knowledge and discover opportunities.

ChinaBio tracks the biotech and life science industries in China. Its proprietary list of CROs and CMOs listed on goBalto is divided into two categories: “Sourced by ChinaBio” and “Reviewed by ChinaBio.” The “Sourced by” designation indicates that ChinaBio has identified these CROs and CMOs as actively operating in China and that information on the company is maintained in its database. “Reviewed by” indicates that ChinaBio has visited the facility, met with senior management and reviewed the company’s specific capabilities. Over 40 of the CROs/CMOs listed on goBalto have been reviewed to date.

“We’re delighted that ChinaBio, a leading consultancy in China, has agreed to make its proprietary list available to the goBalto community,” said Jae Chung, founder and CEO, goBalto. “Interfacing ChinaBio’s list to our platform enables users to more quickly and easily evaluate the leading CROs and CMOs in the region and become informed about the exciting, high-growth China market.”

“goBalto is providing a very valuable service to the drug development community, and we’re happy to be part of their long term strategy,” stated Greg Scott, founder and CEO of ChinaBio. “Through our consulting practice, we work with major pharmas and other companies to identify CROs and CMOs in China that meet their specific needs, and then monitor the projects to help ensure high quality delivery, and goBalto will be an important part of this process.”

According to a recent PricewaterhouseCoopers study, the CRO market in China was $186 million in 2007, up 38% from the year before. Driven mainly by outsourcing from international firms, it is projected to grow at an estimated 33.5% annually, bringing the market to nearly $791 million in 2012. The global CRO market is growing at a much slower 12.6% per year.

The ChinaBio list adds over 260 CROs and CMOs to the list of more than 7,000 potential service providers goBalto has assembled and profiled based on technical capabilities, regulatory compliance, facilities, equipment and other factors. The goBalto platform allows users to rate companies, post comments to vendors and evaluate service providers.


Share this with colleagues:

 

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China